| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | PF-543 | CTRPv2 | pan-cancer | AAC | 0.02 | 0.6 |
| mRNA | KU 0060648 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | pifithrin-alpha | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | TG-101348 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | R428 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.6 |
| mRNA | MK-0752 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.6 |